Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.
Luigi D'AntonioCristiano FieniStefania Livia CiummoSimone VespaLavinia LottiCarlo SorrentinoEmma Di CarloPublished in: Journal for immunotherapy of cancer (2023)
IL30 is a new CRC driver, since its inactivation, which disables oncogenic pathways and multiple autocrine loops, inhibits CR-CSC tumorigenicity and metastatic ability. The development of CRISPR/Cas9-mediated targeting of IL30 could improve the current therapeutic landscape of CRC.